Back

Dual versus triple antithrombotic therapy, does trial design make the difference?

31 August 2020 (12:11 - 12:22)
Organised by:
Congress Presentation Part of: Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Robert Storey

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
A historical perspective: why we opted triple therapy for so long and what made us change our mind.
Professor D. Angiolillo (Jacksonville, US)
Slides Video
Presentation thumbnail
Triple therapy: still an option?
Professor K. Huber (Vienna, AT)
Slides Video
Presentation thumbnail
Dual versus triple antithrombotic therapy - The fine art of personalised medicine.
Professor R. De Caterina (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting

The Event

Event poster

ESC Congress 2020

31 August 2020 12:11 CET
You may be interested in
thumbnail
Congress Presentation
Meta-analysis of clinical trials comparing triple versus dual antithrombotic therapy on risk reduction of stent thrombosis after percutaneous coronary intervention in atrial fibrillation patients
27 August 2021
thumbnail
Congress Presentation
Discussant review - ASSURE DES
31 August 2024
thumbnail
Congress Presentation
Single versus dual antiplatelet therapy following transcatheter left atrial appendage closure
4 April 2022
thumbnail
Congress Presentation
Optimizing antiplatelet therapy in ACS: a network meta-analysis of simplified regimens
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources